Articles tagged "Epitopes"

2020 American Transplant Congress
Clinical Significance of T Cell and B Cell Epitope Prediction as a Risk Factor of De Novo DSA Production after Kidney Transplantation
T. Kobayashi¹, K. Iwasaki¹, T. Tomosugi², Y. Miwa¹, M. Niemann³, E. Spierings⁴, K. Horimi¹, Y. Matsuoka¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: Chronic antibody-mediated rejection caused by de novo DSA (dnDSA) is a major cause of graft failure. Risk prediction of dnDSA would be important for…
2020 American Transplant Congress
Ranking Eplet Mismatches as Predictors of Graft Failure
W. Zhang¹, H. Mohammadhassanzadeh¹, K. Oualkacha², H. Gebel³, W. Klement⁴, R. Sapir-Pichhadze¹
¹McGill University, Montreal, QC, Canada, ²UQAM, Montreal, QC, Canada, ³Emory University Hospital, Atlanta, GA, ⁴Canadian Blood Services, Ottawa, ON, Canada
*Purpose: Donor:recipient matching at the level of sequence defined HLA targets (eplets) is being promoted as a biologically sound strategy to prevent graft failure. Because…
2020 American Transplant Congress
Impact of Eplet Mismatches on the Risk of Graft Loss: Not All Eplets are Created Equal
H. Mohammadhassanzadeh¹, W. Klement², H. Gebel³, B. Foster⁴, P. Keown⁵, K. Oualkacha⁶, R. Sapir-Pichhadze¹
¹Medicine, McGill University, Montreal, QC, Canada, ²Organ Donation and Transplantation, Canadian Blood Services, Ottawa, ON, Canada, ³Emory University Hospital, Atlanta, GA, ⁴Montreal Children's Hospital, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada, ⁶Université du Québec À Montréal, Montreal, QC, Canada
*Purpose: To mitigate risks related to HLA incompatibility, we assessed whether some unique sequence defined HLA targets (eplets) are associated with graft failure while others…
2020 American Transplant Congress
Eplet Mismatch Not Correlated with Antibody Mediated Rejection or Allograft Loss Among Kidney Transplant Recipients with De Novo Donor Specific Antibody
A. Basu¹, W. Jiqiu², A. Bentall², M. Gandhi², B. Dukek², N. Henderson², C. Schinstock²
¹Emory Healthcare, Atlanta, GA, ²Mayo Clinic, Rochester, MN
*Purpose: Eplet mismatches are associated with development of de novo DSA (dnDSA) in kidney transplant recipients. However, it remains unclear how the degree of eplet…
2020 American Transplant Congress
Epitope Analysis of Complement-Binding De Novo Donor-Specific HLA Class II Antibody
K. Yamanaka, M. Hashimoto, T. Kinoshita, Y. Fujita, S. Matsumura, T. Imanaka, A. Taniguchi, T. Yoshida, H. Kishikawa
Department of Kidney Transplantation Center, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan
*Purpose: Patients with de novo donor specific antibody (dnDSA) after kidney transplantation have a poorer prognosis than patients without dnDSA. Meanwhile, patients with dnDSA do…
2020 American Transplant Congress
HLA Diversity Affects Epitope Mismatch Cutoffs Utilized to Predict De Novo DSA Development and Graft Rejection in Renal Transplant Patients
A. Ram¹, S. Dhingra², H. Quach¹, P. T. Jindra¹
¹Immune Evaluation Laboratory-Surgery, Baylor College of Medicine, Houston, TX, ²Pathology, Baylor College of Medicine, Houston, TX
*Purpose: Recent studies have investigated epitope matching in order to determine its predictive power in determining renal transplant outcomes, both in terms of de novo…
2020 American Transplant Congress
Is the Epitope Mismatch Load Enough to Identify HLA-DQ Mismatches with a Low Risk for De Novo DSA Development?
V. Jucaud¹, M. Stegall², C. Schinstock², R. Heilman³, L. Rebellato⁴, M. Samaniego-Picota⁵, D. Leeser⁴, M. Gandhi², J. Beaumont¹, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes. In particular, anti-HLA-DQ dnDSAs,…
2020 American Transplant Congress
HLA Mismatch Immunogenicity: Are We Predicating Mismatches That Induce De Novo DSA Development or That Do Not?
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Although the development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes, the prediction of…
2020 American Transplant Congress
Extended HLA Typing of Kidney Transplant Pairs is Necessary to Assign Presence of Donor-Specific Anti-HLA Antibodies
A. Senev¹, V. Van Sandt², M. Naesens¹, M. Emonds¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²HILA, Rode Kruis Vlaanderen, Leuven, Belgium
*Purpose: The need for extended high-resolution (HR) HLA genotyping in solid organ transplantation is currently widely debated due to higher costs and questioned clinical importance.…
2020 American Transplant Congress
The Eplet-Mismatch Landscape in Kidney Patients and Deceased Donors in British Columbia
J. Tran¹, O. Gunther², J. Lan¹, M. Kadatz¹, R. Sapir-Pichhadze³, P. A. Keown¹
¹University of British Columbia, Vancouver, BC, Canada, ²Gunther Analytics, Vancouver, BC, Canada, ³McGill University, Montreal, QC, Canada
*Purpose: Minimizing quantitative donor/recipient mismatch at the HLA epitope level may optimize graft outcomes in renal transplantation, but the degree to which optimal matching can…